Estradiol and other sex hormone dynamics in menstrual migraine: pathway analysis of hormones in a case-control follow-up study
Abstract
BACKGROUND
Menstrual migraine (MM) is linked to hormonal fluctuations, but the precise role of sex hormones remains unclear. This study hypothesizes that women with MM experience a steeper decline in estradiol before menstruation.
METHODS
In total, 413 standardized serum hormone measurements were collected from 87 menstrual cycles contributed by 46 participants (28 with MM, 18 healthy controls) in this prospective cohort study. Blood samples were collected on standardized cycle days based on the luteinizing hormone surge (day 0), specifically on days 1, 2, 3, 8, 10, 12, and 14 post-surge, covering mid- and late-luteal phases. The primary outcome was the peak estradiol level during the mid-luteal phase (day 8) and its subsequent decline from day 8 to day 14. Secondary outcomes included levels of other sex hormones such as steroids (progesterone, testosterone), gonadotropins, and androgens, as well as hormone pair ratios.
RESULTS
Women with MM had a 49% higher peak estradiol level during the luteal phase (1.49, 95% CI: 1.03-1.87, P = .04) and a 90% greater decline from mid- to late-luteal phase compared to controls (1.90, 95% CI: 1.16-3.12, P = .03). Secondary pathway analysis showed no differences in other sex hormones, although progesterone showed high variability and a peak difference of similar magnitude to estradiol.
DISCUSSION
Women with MM have a higher peak estradiol and a more pronounced estradiol decline during the luteal phase compared to controls, indicating that…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 46 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.